Compare LENZ & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LENZ | TNYA |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.5M | 168.2M |
| IPO Year | 2021 | 2021 |
| Metric | LENZ | TNYA |
|---|---|---|
| Price | $4.58 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $44.00 | $5.33 |
| AVG Volume (30 Days) | 817.7K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | N/A |
| Revenue This Year | $50.42 | N/A |
| Revenue Next Year | $197.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $0.53 |
| 52 Week High | $50.19 | $2.35 |
| Indicator | LENZ | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 38.79 |
| Support Level | N/A | $0.65 |
| Resistance Level | $6.18 | $0.81 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 2.49 | 9.97 |
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.